Glatiramer Acetate
An FDA-approved immunomodulatory peptide mixture for relapsing-remitting multiple sclerosis (MS).
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Glatiramer Acetate?
Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids (glutamic acid, lysine, alanine, tyrosine) in a specific molar ratio. It is FDA-approved for relapsing forms of multiple sclerosis. It works by shifting the immune response from pro-inflammatory Th1 to anti-inflammatory Th2, reducing MS relapses by approximately 30%.
Why People Talk About It
Relapsing-remitting MS treatment
StrongImmune system modulation (Th1 to Th2 shift)
StrongNeuroprotective effects
ModerateHow It Works
Glatiramer acetate looks like the myelin coating on nerves that the immune system mistakenly attacks in MS. It acts as a decoy, redirecting the immune attack and shifting immune cells from harmful to protective mode.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Injection site rotation is important
- • Post-injection reaction can be alarming but is self-limiting
- • Not for progressive MS
What We Don't Know
Well-characterized safety profile with over 25 years of clinical use. One of the safest MS therapies available.
Published Research
34 studiesAssessing the Role of Cannabis in Managing Spasticity in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Rituximab for people with multiple sclerosis
Effectiveness of combination therapy versus monotherapy in multiple sclerosis: A systematic review and meta-analysis
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
Decision Curve Analysis for Personalized Treatment Choice between Multiple Options
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis
Disease-modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta-analysis
A two-stage prediction model for heterogeneous effects of treatments
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis
Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review
A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments
Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis
Alemtuzumab for multiple sclerosis
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis
Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Dimethyl fumarate for multiple sclerosis
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis
Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
Quick Facts
- Class
- Immunomodulatory Peptide Mixture
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 34PubMed
Also known as
Tags
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician